Montair Chewable 4 mg Cipla

£12.00

Montair Chewable 4 mg by Cipla contains montelukast sodium, a leukotriene receptor antagonist studied for respiratory inflammation pathways in laboratory research applications.

 

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
Montair Chewable 4 mg Cipla
Montair Chewable 4 mg Cipla
£12.00

[wpforms id=”1190″ title=”true” description=”Request a call back”]

Research Overview of Montair Chewable 4mg

Montair Chewable 4mg is a pharmaceutical preparation containing montelukast sodium as the active ingredient, manufactured by Cipla. Montelukast belongs to the class of leukotriene receptor antagonists, specifically targeting the cysteinyl leukotriene type 1 (CysLT1) receptor. This compound is extensively studied in respiratory research for its role in modulating inflammatory pathways associated with bronchoconstriction and allergic responses. The chewable formulation provides researchers with convenient oral administration options for laboratory studies examining dose-response relationships and bioavailability profiles. Montair represents a valuable research tool for investigating leukotriene-mediated inflammatory processes and their therapeutic modulation. Researchers at Stroid UK Shop can access this compound alongside comprehensive documentation for rigorous experimental protocols.

Laboratory Research Applications

In experimental settings, montelukast serves as a selective antagonist for studying cysteinyl leukotriene pathways in inflammatory models. Research applications include investigation of allergic rhinitis mechanisms, exercise-induced bronchoconstriction studies, and aspirin-sensitive respiratory condition models. The compound demonstrates high selectivity for CysLT1 receptors with minimal activity at other leukotriene or prostaglandin receptors, making it valuable for pathway-specific research. Scientists examine its effects on eosinophil recruitment, mast cell degranulation, and cytokine production in controlled laboratory environments. Comparative studies often evaluate montelukast against other anti-inflammatory compounds available through our specialised pharmaceutical research category. The chewable formulation enables precise dosing studies and pharmacokinetic analysis in experimental models requiring oral administration routes.

Compound Specifications

Montair Chewable 4mg Technical Specifications
Active Ingredient Montelukast Sodium
Strength 4mg per chewable tablet
Manufacturer Cipla Limited
CAS Number Verify with supplier
Molecular Formula Verify with supplier
Storage Requirements Room temperature, dry environment
Research Applications Leukotriene pathway studies, respiratory inflammation
Form Chewable tablets

Researchers requiring additional research compounds can explore our extensive SARMS collection or peptide research materials for comprehensive experimental protocols.

Research Compliance Information

Montair Chewable 4mg is supplied exclusively for in-vitro laboratory research purposes and is not intended for human consumption or therapeutic use. This product is restricted to qualified research institutions and licensed laboratories conducting approved studies on leukotriene receptor mechanisms and respiratory inflammation pathways. Researchers must ensure appropriate institutional oversight, proper handling protocols, and compliance with relevant laboratory safety guidelines when working with this compound. All experimental work should be conducted within appropriate containment facilities with adequate ventilation and personal protective equipment. This product has not been evaluated for human safety or efficacy and must remain within controlled research environments at all times.

Related